{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:40:44Z","timestamp":1685439644324},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.clinthera.2010.01.008","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T09:27:14Z","timestamp":1266485234000},"page":"108-118","source":"Crossref","is-referenced-by-count":7,"title":["Diffusion of a new drug: A comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands"],"prefix":"10.1016","volume":"32","author":[{"given":"Petros","family":"Pechlivanoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"Vehof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Agthoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolkje T.W.","family":"de Jong-van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.01.008_bib1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1756-2171.2006.tb00033.x","article-title":"The role of firm characteristics in pharmaceutical product launches","volume":"37","author":"Kyle","year":"2006","journal-title":"RAND J Econ."},{"key":"10.1016\/j.clinthera.2010.01.008_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijresmar.2004.05.001","article-title":"Diffusion of new pharmaceutical drugs in developing and developed nations","volume":"21","author":"Desiraju","year":"2004","journal-title":"Int J Res Market"},{"key":"10.1016\/j.clinthera.2010.01.008_bib3","series-title":"NBER Working Paper No. 14252","article-title":"Information, learning, and drug diffusion: The case of cox-2 inhibitors","author":"Chintagunta","year":"2008"},{"key":"10.1016\/j.clinthera.2010.01.008_bib4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/pds.1248","article-title":"The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France","volume":"15","author":"Olivier","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.clinthera.2010.01.008_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ps.57.5.700","article-title":"Psychiatric decision making in the adoption of a new antipsychotic in Germany","volume":"57","author":"Hamann","year":"2006","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.clinthera.2010.01.008_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.ps.57.1.70","article-title":"Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system","volume":"57","author":"Valenstein","year":"2006","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.clinthera.2010.01.008_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.schbul.a006995","article-title":"The diffusion of new antipsychotic medications and formulary policy","volume":"29","author":"Domino","year":"2003","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.clinthera.2010.01.008_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/070674370204700904","article-title":"Prevalence and incidence studies of schizophrenic disorders: A systematic review of the literature","volume":"47","author":"Goldner","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.008_bib9","series-title":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020","author":"Murray","year":"1996"},{"key":"10.1016\/j.clinthera.2010.01.008_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1176\/ajp.154.2.199","article-title":"Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders","volume":"154","author":"Fenton","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.008_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ajp.156.8.1138","article-title":"Treatment of schizoaffective disorder and schizophrenia with mood symptoms","volume":"156","author":"Levinson","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"Suppl 23","key":"10.1016\/j.clinthera.2010.01.008_bib12","first-page":"20","article-title":"The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment","volume":"60","author":"Gerlach","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.008_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psych."},{"key":"10.1016\/j.clinthera.2010.01.008_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.01.008_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1192\/apt.11.3.203","article-title":"Why aren't depot antipsychotics prescribed more often and what can be done about it?","volume":"11","author":"Patel","year":"2005","journal-title":"Adv Psych Treat."},{"key":"10.1016\/j.clinthera.2010.01.008_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2165\/00003495-200767110-00003","article-title":"Long-acting injectable risperidone for the treatment of schizophrenia: Clinical perspectives","volume":"67","author":"M\u00f6ller","year":"2007","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.01.008_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.882","article-title":"How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information","volume":"13","author":"Schirm","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.clinthera.2010.01.008_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pds.951","article-title":"Refill rate of antipsychotic drugs: An easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data","volume":"13","author":"Rijcken","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.clinthera.2010.01.008_bib19","series-title":"Bipolar Medications: Mechanisms of Action","year":"2000"},{"key":"10.1016\/j.clinthera.2010.01.008_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1061\/(ASCE)1084-0699(2000)5:1(59)","article-title":"Estimation of harmonic mean of a lognormal variable","volume":"5","author":"Limbrunner","year":"2000","journal-title":"J Hydrologic Eng."},{"key":"10.1016\/j.clinthera.2010.01.008_bib21","series-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"Sokal","year":"1995"},{"key":"10.1016\/j.clinthera.2010.01.008_bib22","series-title":"Handbook of Data Analysis","year":"2004"},{"key":"10.1016\/j.clinthera.2010.01.008_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<813::AID-SIM775>3.0.CO;2-#","article-title":"A generalized F mixture model for cure rate estimation","volume":"17","author":"Peng","year":"1998","journal-title":"Stat Med."},{"key":"10.1016\/j.clinthera.2010.01.008_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/appi.ps.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.clinthera.2010.01.008_bib25","series-title":"Dutch Pharmacoeconomic Guidelines 2008 [in Dutch]","year":"2008"},{"key":"10.1016\/j.clinthera.2010.01.008_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00757.x","article-title":"Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia","volume":"430","author":"Williams","year":"2006","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"10.1016\/j.clinthera.2010.01.008_bib27","series-title":"Dynamic Regression Models for Survival Data","author":"Martinussen","year":"2006"},{"key":"10.1016\/j.clinthera.2010.01.008_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2307\/2288398","article-title":"Reducing bias in observational studies using subclassification on propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc."},{"key":"10.1016\/j.clinthera.2010.01.008_bib29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/NDT.S3311","article-title":"Risperidone long-acting injection: A review of its long term safety and efficacy","volume":"4","author":"Rainer","year":"2008","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.clinthera.2010.01.008_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0447.2006.00980.x","article-title":"Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care","volume":"116","author":"Niaz","year":"2007","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.clinthera.2010.01.008_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/pb.28.1.12","article-title":"Risperidone long-acting injection: The first 50 patients","volume":"28","author":"Paton","year":"2004","journal-title":"Psychiatr Bull."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:58:35Z","timestamp":1685437115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0149291810000093"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}